Evidence map›Paper›PMID 33216119›Full record

ArticleInvestigative ophthalmology & visual science2020

Lysophosphatidic Acid and IL-6 Trans-signaling Interact via YAP/TAZ and STAT3 Signaling Pathways in Human Trabecular Meshwork Cells.

Felix Yemanyi, VijayKrishna Raghunathan

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. The Hippo signalling pathway and its impact on eye diseases.Journal of cellular and molecular medicine · 2024
    Pooled it
  3. Article
  4. Review
  5. Mechanobiology in the eye.npj biological physics and mechanics · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ocular Biomechanics and Glaucoma.Vision (Basel, Switzerland) · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Long Non-coding RNA GAS5 Knockdown Attenuates HJournal of molecular neuroscience : MN · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Felix YemanyiCollege of Optometry, University of Houston, Houston, Texas, United States.
VijayKrishna RaghunathanCollege of Optometry, University of Houston, Houston, Texas, United States.
University of Houston · US

Funding

Research Programming ModuleP30EY007551 · NEI · UNIVERSITY OF HOUSTON · PI LAURA J. FRISHMAN · 1988 to 2026
$16.4M
Mechanotransduction in Aqueous Outflow Regulation and Open Angle GlaucomaR01EY026048 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ACOTT, TED S, RAGHUNATHAN, VIJAYKRISHNA · 2018 to 2021
$1.5M
NEI NIH HHS P30 EY007551NEI NIH HHS R01 EY026048
6 · The paper itself

Abstract

Purpose: Lysophosphatidic acid (LPA) and soluble interleukin-6 receptor (sIL6R) are elevated in primary open angle glaucoma (POAG). LPA and IL6 modulate in response to biomechanical stimuli and converge on similar fibrotic phenotypes. Thus, we determined whether LPA and IL6 trans-signaling (IL6/sIL6R) interact via Yes-associated protein (YAP)/Transcriptional coactivator with a PDZ-binding motif (TAZ) or Signal transducer and activator of transcription 3 (STAT3) pathways in human trabecular meshwork (hTM) cells. Methods: Confluent primary hTM cells were serum starved for 24 hours, and treated with vehicle, LPA (20 µM), IL6 (100 ng/mL)/sIL6R (200 ng/mL), or both (LPA + IL6/sIL6R) for 24 hours, with or without a YAP inhibitor (verteporfin; 2 µM) or STAT3 inhibitor (2 µM). Expression of key receptors and ligands, signaling mediators, actomyosin machinery, cell contractility, and extracellular matrix (ECM) targets of both signaling pathways was determined by immunocytochemistry, RT-qPCR, and Western blotting. Results: LPA and IL6 trans-signaling coupling overexpressed/activated receptors and ligands, glycoprotein-130, IL6, and autotaxin; signaling mediators, YAP, TAZ, Pan-TEAD, and phosphorylated STAT3 (pSTAT3); actomyosin and contractile machinery components, myosin light chain 2 (MLC2), phosphorylated MLC2, rho-associated protein kinase 1, filamentous actin, and α-smooth muscle actin; and fibrotic ECM proteins, collagen I and IV, fibronectin, laminin, cysteine-rich angiogenic inducer 61, and connective tissue growth factor in hTM cells; mostly beyond LPA or IL6 trans-signaling alone. Verteporfin inhibited YAP, TAZ, and pSTAT3, with concomitant abrogation of aforementioned fibrotic targets; the STAT3 inhibitor was only partially effective. Conclusions: These data suggest synergistic crosstalk between LPA and IL6 trans-signaling, mediated by YAP, TAZ, and pSTAT3. By completely inhibiting these mediators, verteporfin may be more efficacious in ameliorating LPA and/or IL6 trans-signaling-induced ocular hypertensive phenotypes in hTM cells.

Indexed as

Signal TransductionAdaptor Proteins, Signal TransducingAgedBlotting, WesternCells, CulturedCytokine Receptor gp130HumansImmunohistochemistryInterleukin-6LysophospholipidsMiddle AgedReal-Time Polymerase Chain ReactionReceptors, Interleukin-6Receptors, Lysophosphatidic AcidSTAT3 Transcription FactorTrabecular MeshworkAdaptor Proteins, Signal TransducingCytokine Receptor gp130Interleukin-6LPAR1 protein, humanLPAR6 protein, humanlysophosphatidic acidLysophospholipidsReceptors, Interleukin-6Receptors, Lysophosphatidic AcidSTAT3 protein, humanSTAT3 Transcription FactorTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID33216119
PMCPMC7683860
OpenAlexW3106224792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.